Previous close | 8.08 |
Open | 8.13 |
Bid | 6.85 |
Ask | 7.50 |
Strike | 85.00 |
Expiry date | 2026-01-16 |
Day's range | 8.08 - 8.13 |
Contract range | N/A |
Volume | |
Open interest | 452 |
Novavax stock is soaring on news the FDA set a deadline by which to approve or reject its COVID-19 vaccine.
On Friday, Moderna Inc. (NASDAQ:MRNA) announced that it has submitted an FDA application for review of its Spikevax 2024-2025 formula, which targets the SARS-CoV-2 variant JN.1. The submission is based on FDA guidance, which advised that COVID-19 vaccines should be updated to a monovalent JN.1 composition for the 2024-2025 season. JN.1 and its descendants KP.2 and KP.3 are the versions of the virus that are most common in the U.S. right now, according to the US Centers for Disease Control and Pr
Moderna stock is on the rise amid a bevy of news, including FDA approval for its RSV vaccine. Is MRNA stock a buy right now?